A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer
Completed · Phase 1
Conditions studied: Advanced Cancer
In brief
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and docetaxel (with prophylactic growth factor support). Patients will receive increasing doses of study drug in combination with docetaxel in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 30 patients from the US will be enrolled in this study.
Key facts
- Study ID
- NCT00833326
- Run by
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- People needed
- 27
- Starts
- 2009-01-01
- Expected to finish
- 2010-07-01
- Last updated by the study team
- 2020-10-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Colorado Health Sciences Center — Aurora, Colorado, United States
- Mayo Cancer Center — Rochester, Minnesota, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.